Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

May 23, 2019

Study Completion Date

May 23, 2019

Conditions
Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Pentamidine

Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.

Trial Locations (1)

40536

University of Kentucky Markey Cancer Center, Lexington

All Listed Sponsors
lead

Reinhold Munker

OTHER

NCT03730363 - Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter